Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Phase II Multicenter Trial of Lenalidomide: Clinical and Immunomodulatory Effects in Patients with CTCL

Christiane Querfeld, MD, PhD, Steven T. Rosen, MD, Joan Guitart, MD, Madeleine Duvic, MD, Youn H. Kim, MD, Charles Goolsby, PhD, Timothy Kuzel, MD

Blood (2011) 118 (21): 1638.

https://doi.org/10.1182/blood.V118.21.1638.1638

Published: 2011

Journal Articles

Normal bone marrow signal-transduction profiles: a requisite for enhanced detection of signaling dysregulations in AML

James Marvin, Suchitra Swaminathan, Geoffrey Kraker, Amy Chadburn, James Jacobberger, Charles Goolsby

Blood (2011) 117 (15): e120–e130.

https://doi.org/10.1182/blood-2010-10-316026

Published: 2011

Journal Articles

Alemtuzumab and Rituximab Combination Therapy for Patients with Untreated CLL – a Phase II Trial.

Olga Frankfurt, Elizabeth Hamilton, Sara Duffey, Simbi Acharya, Adekunle Raji, Shuo Ma, Loann Peterson, Charles Goolsby, Steven T. Rosen

Blood (2008) 112 (11): 2098.

https://doi.org/10.1182/blood.V112.11.2098.2098

Published: 2008

Journal Articles

ZAP-70 Expression in Chronic Lymphocytic Leukemia Is Associated with Altered Signal Transduction.

Kristy L. Wolniak, MD, PhD, James Marvin, B.S., Charles Goolsby, Ph.D.

Blood (2007) 110 (11): 4702.

https://doi.org/10.1182/blood.V110.11.4702.4702

Published: 2007

Journal Articles

Concurrent Treatment with Denileukin Diftitox (DD) To Deplete T-Regulatory Cells Enhances Rebound Lymphocytosis and Eosinophilia in Patients Treated with High-Dose IL-2 (HDIL-2) for Metastatic Renal Cell Cancer (MRCC).

Adi Gidron, MD, John Eklund, MD, Brenda Martone, RN, MSN, Alfred W. Rademaker, PhD, Charles Goolsby, PhD, Laura Marszalek, Timothy M. Kuzel, MD

Blood (2006) 108 (11): 1729.

https://doi.org/10.1182/blood.V108.11.1729.1729

Published: 2006

Journal Articles

Treatment of Autoimmune Disease by Intense Immunosuppressive Conditioning and Autologous Hematopoietic Stem Cell Transplantation

Blood (1998) 92 (10): 3505–3514.

https://doi.org/10.1182/blood.V92.10.3505

Published: 1998

NARROW

Phase II Multicenter Trial of Lenalidomide: Clinical and Immunomodulatory Effects in Patients with CTCL

Normal bone marrow signal-transduction profiles: a requisite for enhanced detection of signaling dysregulations in AML

Alemtuzumab and Rituximab Combination Therapy for Patients with Untreated CLL – a Phase II Trial.

ZAP-70 Expression in Chronic Lymphocytic Leukemia Is Associated with Altered Signal Transduction.

Concurrent Treatment with Denileukin Diftitox (DD) To Deplete T-Regulatory Cells Enhances Rebound Lymphocytosis and Eosinophilia in Patients Treated with High-Dose IL-2 (HDIL-2) for Metastatic Renal Cell Cancer (MRCC).

Treatment of Autoimmune Disease by Intense Immunosuppressive Conditioning and Autologous Hematopoietic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Phase II Multicenter Trial of Lenalidomide: Clinical and Immunomodulatory Effects in Patients with CTCL

Normal bone marrow signal-transduction profiles: a requisite for enhanced detection of signaling dysregulations in AML

Alemtuzumab and Rituximab Combination Therapy for Patients with Untreated CLL – a Phase II Trial.

ZAP-70 Expression in Chronic Lymphocytic Leukemia Is Associated with Altered Signal Transduction.

Concurrent Treatment with Denileukin Diftitox (DD) To Deplete T-Regulatory Cells Enhances Rebound Lymphocytosis and Eosinophilia in Patients Treated with High-Dose IL-2 (HDIL-2) for Metastatic Renal Cell Cancer (MRCC).

Treatment of Autoimmune Disease by Intense Immunosuppressive Conditioning and Autologous Hematopoietic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only